Mycobacteria for NEET PG Microbiology: Tuberculosis Under NTEP, Drug-Resistant TB, NTM and Leprosy (NLEP 2025)

Start Here

🎯 Exam priority: Very high. Expect: droplet-nuclei spread, Ghon vs Ranke complex, latent reactivation risk, sites of reactivation, Xpert/Truenat, liquid vs LJ culture times, TST/BCG, the NTEP DS-TB regimen and doses, the new DR-TB definitions (pre-XDR, XDR) and BPaLM, TPT for contacts, NTM matching (MAC, marinum, ulcerans, scrofulaceum), and leprosy PB/MB criteria, MDT duration and reactions.

CBME mapping: MI7.3, MI5.4. Fact-checked against the MSD Manual, the ICMR–NTEP DS-TB workflow (2022), NTEP DR-TB (2025) and TPT (2021) guidelines, the India TB Report 2024 and NLEP (2025).

Tuberculosis spread, diagnosis, Indian regimens and drug-resistance definitions, non-tuberculous mycobacteria and leprosy

TB, drug resistance, NTM and leprosy. Drawn by TrackNation.

The Organism and the Disease (MSD)

  • Mycobacteria are slow-growing aerobic bacilli with a mycolic-acid envelope — acid-fast and poorly Gram-staining. The M. tuberculosis complex includes M. tuberculosis, M. bovis, M. africanum and M. microti.

  • Spread is by droplet nuclei (1–5 µm) from people with active pulmonary or laryngeal TB; cavitary disease is most infectious. Primary and latent infection are usually not transmissible.

  • >90–95% of primary infections are asymptomatic. A primary focus is a Ghon focus; with its node it is a Ghon complex; calcified, a Ranke complex. 5 to <10% of latent infections reactivate — favoured sites are the apical-posterior lung, kidneys, epiphyses, vertebrae and meninges.

  • Suspect TB with cough >2–3 weeks, haemoptysis, night sweats, weight loss. HIV is the strongest risk factor; presentations are atypical. India 2023: 25.52 lakh notified cases; estimated incidence 199 per lakh (217 in 2015).

Diagnosis (MSD, NTEP)

  • Smear (ZN/auramine; needs ≥10,000 bacilli/mL — article 04), NAATs and culture. Xpert MTB/RIF (Ultra) and Truenat detect M. tuberculosis DNA in about 2 hours and rifampicin resistance.

  • Culture: liquid media are faster and more sensitive (2–3 weeks) than Lowenstein–Jensen (≥4 weeks); hold 8 weeks. Liquid-culture DST guides DR-TB regimens.

  • Screening for infection: tuberculin skin test or IGRA; BCG's effect on TST wanes after several years.

Treatment and Prevention in India (NTEP)

Timeline of the NTEP drug-sensitive TB regimen: HRZE for 8 weeks then HRE for 16 weeks, extended in CNS and skeletal TB

The NTEP drug-sensitive TB regimen 2HRZE/4HRE as a timeline. Drawn by TrackNation.

  • DS-TB (ICMR–NTEP 2022): 2HRZE / 4HRE daily weight-band FDCs — intensive phase 8 weeks (56 doses), continuation 16 weeks (112 doses), extended to 24 weeks for CNS and skeletal TB. Doses: H 5, R 10, Z 25, E 15 mg/kg; pyridoxine 10 mg/day.

  • Drug-resistance definitions (NTEP 2025): RR-TB — rifampicin resistance; MDR-TB — H + R; pre-XDR — MDR/RR + any fluoroquinolone; XDR — MDR/RR + fluoroquinolone + bedaquiline or linezolid; Hr-TB — isoniazid-resistant, rifampicin-sensitive.

  • Regimens: BPaLM (bedaquiline, pretomanid, linezolid 600 mg, moxifloxacin 400 mg) for 6 months (26 weeks, extendable) in eligible patients; otherwise the 9–11-month shorter oral or 18–20-month longer oral regimen.

  • TPT (NTEP 2021): all household contacts of pulmonary TB, any age, after ruling out active TB; under-5s need no infection test. Options include 6H (daily isoniazid, 6 months), 3HP (weekly rifapentine + isoniazid, 3 months); 6Lfx (levofloxacin, 6 months) for contacts of rifampicin-resistant, fluoroquinolone-sensitive TB; 4R for contacts of isoniazid-resistant TB.

NTM and Leprosy (MSD, NLEP)

  • NTM: lungs commonest site; MAC (M. avium, M. intracellulare) causes most disease — prophylaxis in HIV with CD4 <50 when not suppressed; treated with a macrolide + rifampicin/rifabutin + ethambutol. M. abscessus can spread between cystic-fibrosis patients. M. marinum — swimming-pool / fish-tank granuloma; M. ulcerans — Buruli ulcer (grows at 32 °C over up to 12 weeks); child cervical lymphadenitis — MAC or M. scrofulaceum.

  • Leprosy (M. leprae; M. lepromatosis since 2008): affinity for peripheral nerves, skin and upper-airway mucosa; spread by nasal droplets, not casual contact; ~95% of exposed people never develop disease; peaks at 5–15 and >30 years; armadillos are a zoonotic reservoir in the US.

  • Spectrum: tuberculoid — strong cell-mediated immunity, few lesions (paucibacillary); lepromatous — weak CMI, widespread bacilli (multibacillary). Reactions: type 1 = reversal; type 2 = erythema nodosum leprosum (immune complex), less common since clofazimine.

  • NLEP (2023 classification, 2025 regimen): PB = 1–5 lesions, no nerve, slit-skin smear negative; MB = >5 lesions, nerve involvement, smear positive. Both get 3-drug MDT — rifampicin 600 mg monthly, clofazimine 300 mg monthly + 50 mg daily, dapsone 100 mg daily — PB 6 months, MB 12 months. Leprosy became notifiable in 2025; contacts get single-dose rifampicin. Prevalence 0.57 per 10,000 (2024–25).

Traps the Examiner Sets

  • Ranke = calcified Ghon complex.

  • Pre-XDR adds fluoroquinolone resistance; XDR adds bedaquiline or linezolid resistance too.

  • India's NLEP now gives clofazimine to PB patients as well — 3 drugs for 6 months.

  • Fish-tank granuloma is M. marinum; Buruli ulcer is M. ulcerans.

  • Under-5 household contacts get TPT without a TST or IGRA once active TB is excluded.

Memory Hooks & Shortcuts

Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.

  • 🧠 'Ghon goes Gone-calcified = Ranke' — R for Rock-hard calcium — TB pathology

  • 🧠 NTEP doses '5-10-25-15': H-R-Z-E mg/kg — DS-TB

  • 🧠 Resistance ladder 'R → M → Pre → X': Rif, then H+R, then +FQ, then +Bdq/Lzd — DR-TB

  • 🧠 'Fish Marinum, Buruli Ulcerans, Avium for AIDS' — NTM

  • 🧠 'PB = Pretty Brief (6 months), MB = Much Bigger (12 months) — same 3 drugs now' — leprosy

Rapid-Revision Cards

  • Mycolic acid

    Acid-fast; poor Gram stain.

  • MTB complex

    M. tb, bovis, africanum, microti.

  • Spread

    Droplet nuclei 1–5 µm.

  • Ghon / Ranke

    Focus + node / calcified complex.

  • Latent → active

    5 to <10%.

  • Reactivation site

    Apical-posterior lung.

  • Xpert / Truenat

    DNA + rifampicin R in ~2 h.

  • Culture

    Liquid 2–3 wk; LJ ≥4 wk.

  • DS-TB

    2HRZE / 4HRE; CP 24 wk for CNS, bone.

  • Doses

    H5 R10 Z25 E15 mg/kg.

  • MDR

    H + R.

  • Pre-XDR / XDR

    +FQ / +FQ + Bdq or Lzd.

  • BPaLM

    6 months; Bdq, Pa, Lzd, Mfx.

  • TPT

    All HHC; <5 y no test; 6H, 3HP.

  • MAC

    Most NTM; HIV CD4 <50.

  • M. marinum

    Fish-tank granuloma.

  • M. ulcerans

    Buruli ulcer.

  • Leprosy tropism

    Nerves, skin, nasal mucosa.

  • NLEP PB / MB

    1–5, no nerve, SSS − / >5, nerve, SSS +.

  • NLEP MDT

    R + C + D: PB 6 mo, MB 12 mo.

  • Lepra reactions

    Type 1 reversal; type 2 ENL.

Sources

Facts in this article were checked against these documents.

  • MSD Manual Professional: Tuberculosis; Nontuberculous Mycobacterial Infections; Leprosy; Culture — Merck & Co. (MSD Manuals), 2024–26 (link)

  • Standard Treatment Workflow: Drug-Sensitive TB Treatment as per NTEP — ICMR / Department of Health Research, 2022

  • Guidelines for Programmatic Management of Drug-Resistant TB in India — Central TB Division, MoHFW, 2024–25

  • Guidelines for Programmatic Management of TB Preventive Treatment in India — Central TB Division, MoHFW, 2021

  • India TB Report 2024 — Central TB Division, MoHFW, 2024

  • National Leprosy Eradication Programme — Directorate General of Health Services, MoHFW, 2025

  • Competency Based Undergraduate Curriculum, Vol I: Microbiology (MI7.3, MI5.4) — National Medical Commission, 2024

Test Yourself: Practice Questions

Thirty questions in NEET PG style, many of them programme and clinical scenarios.

Practice Questions (NEET PG pattern)

Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.

Q1. Mycobacteria resist Gram staining and are acid-fast because of

  • (a) mycolic acid in a lipid-rich envelope

  • (b) spores

  • (c) a thick capsule

  • (d) lack of peptidoglycan

Show answer

Answer: (a) — MSD.


Q2. The M. tuberculosis complex includes M. tuberculosis and

  • (a) M. leprae

  • (b) M. avium and M. intracellulare

  • (c) M. bovis, M. africanum and M. microti

  • (d) M. marinum

Show answer

Answer: (c) — MSD.


Q3. TB is transmitted mainly by

  • (a) droplet nuclei of 1–5 µm from people with active pulmonary TB

  • (b) faeco-oral route

  • (c) fomites

  • (d) insect vectors

Show answer

Answer: (a) — Cavitary disease most infectious.


Q4. A calcified primary focus with its calcified hilar node on chest X-ray is a

  • (a) Simon focus

  • (b) Ranke complex

  • (c) Ghon focus

  • (d) Assmann focus

Show answer

Answer: (b) — Ghon complex when not calcified.


Q5. The proportion of latent TB infections that later reactivate is about

  • (a) 50%

  • (b) 5 to less than 10%

  • (c) 90%

  • (d) under 0.1%

Show answer

Answer: (b) — Higher with HIV.


Q6. Reactivation pulmonary TB typically involves the

  • (a) apical-posterior segments of the lung

  • (b) middle lobe only

  • (c) lingula

  • (d) lower lobes

Show answer

Answer: (a) — MSD.


Q7. The single most important factor predisposing to TB disease and death where both infections are common is

  • (a) diabetes

  • (b) HIV infection

  • (c) alcohol

  • (d) smoking

Show answer

Answer: (b) — Atypical presentation.


Q8. Xpert MTB/RIF and Truenat tests detect M. tuberculosis DNA and

  • (a) rifampicin resistance, in about 2 hours

  • (b) all drug resistance

  • (c) latent TB

  • (d) isoniazid resistance only

Show answer

Answer: (a) — MSD.


Q9. Compared with Lowenstein–Jensen medium, liquid culture for M. tuberculosis is

  • (a) less sensitive

  • (b) slower

  • (c) not used

  • (d) faster and more sensitive (2–3 weeks)

Show answer

Answer: (d) — LJ ≥4 weeks.


Q10. TB infection is screened for with

  • (a) sputum culture only

  • (b) Widal

  • (c) tuberculin skin test or interferon-gamma release assay

  • (d) chest X-ray only

Show answer

Answer: (c) — MSD.


Q11. The NTEP regimen for drug-sensitive TB is

  • (a) 9HR

  • (b) 2HRZE / 4HR thrice weekly

  • (c) 6HRZE

  • (d) 2HRZE / 4HRE

Show answer

Answer: (d) — Daily FDCs.


Q12. In the NTEP DS-TB regimen, the drug stopped after the intensive phase is

  • (a) pyrazinamide

  • (b) rifampicin

  • (c) isoniazid

  • (d) ethambutol

Show answer

Answer: (a) — ICMR–NTEP STW.


Q13. For TB meningitis and skeletal TB, NTEP extends the continuation phase to

  • (a) 4 weeks

  • (b) 52 weeks

  • (c) 24 weeks

  • (d) 8 weeks

Show answer

Answer: (c) — ICMR–NTEP STW.


Q14. The daily dose of rifampicin in adult DS-TB (NTEP) is

  • (a) 10 mg/kg

  • (b) 25 mg/kg

  • (c) 15 mg/kg

  • (d) 5 mg/kg

Show answer

Answer: (a) — H 5, Z 25, E 15.


Q15. MDR-TB is resistance to

  • (a) isoniazid and rifampicin

  • (b) ethambutol and pyrazinamide

  • (c) rifampicin alone

  • (d) any fluoroquinolone

Show answer

Answer: (a) — NTEP.


Q16. Pre-XDR TB is MDR/RR-TB with additional resistance to

  • (a) bedaquiline and linezolid

  • (b) any fluoroquinolone

  • (c) ethambutol

  • (d) streptomycin

Show answer

Answer: (b) — NTEP 2025.


Q17. XDR-TB (current definition) is MDR/RR-TB resistant to a fluoroquinolone and

  • (a) bedaquiline or linezolid

  • (b) an injectable aminoglycoside

  • (c) pyrazinamide

  • (d) isoniazid only

Show answer

Answer: (a) — Group A drug.


Q18. The 6-month all-oral regimen prioritised for eligible MDR/RR-TB patients is

  • (a) 2HRZE/4HRE

  • (b) streptomycin-based

  • (c) BPaLM

  • (d) 18–20 month longer regimen

Show answer

Answer: (c) — Bedaquiline, pretomanid, linezolid, moxifloxacin.


Q19. Under NTEP TPT guidelines, a 3-year-old household contact of a sputum-positive patient, with active TB excluded, should

  • (a) receive TPT without TST or IGRA

  • (b) receive full ATT

  • (c) receive nothing

  • (d) have IGRA first

Show answer

Answer: (a) — NTEP 2021.


Q20. 3HP preventive therapy is

  • (a) levofloxacin for 6 months

  • (b) weekly rifapentine plus isoniazid for 3 months

  • (c) daily isoniazid for 3 months

  • (d) daily rifampicin for 4 months

Show answer

Answer: (b) — NTEP.


Q21. Most non-tuberculous mycobacterial disease is due to

  • (a) M. ulcerans

  • (b) M. marinum

  • (c) Mycobacterium avium complex

  • (d) M. kansasii

Show answer

Answer: (c) — M. avium + M. intracellulare.


Q22. A nodular ulcerating lesion on the hand of someone who cleans a home aquarium is due to

  • (a) M. ulcerans

  • (b) Mycobacterium marinum

  • (c) M. leprae

  • (d) Sporothrix

Show answer

Answer: (b) — Fish-tank granuloma.


Q23. Buruli ulcer is caused by

  • (a) M. abscessus

  • (b) M. ulcerans

  • (c) M. fortuitum

  • (d) M. marinum

Show answer

Answer: (b) — Grows at 32 °C.


Q24. In people with HIV not on effective ART, MAC prophylaxis is indicated when CD4 is below

  • (a) 200 cells/µL

  • (b) 500 cells/µL

  • (c) 350 cells/µL

  • (d) 50 cells/µL

Show answer

Answer: (d) — MSD.


Q25. M. leprae shows special tropism for

  • (a) peripheral nerves, skin and upper-airway mucosa

  • (b) bone marrow

  • (c) liver and spleen only

  • (d) the CNS

Show answer

Answer: (a) — MSD.


Q26. Leprosy is transmitted mainly through

  • (a) insect bites

  • (b) casual touch

  • (c) blood transfusion

  • (d) nasal droplets and secretions with prolonged contact

Show answer

Answer: (d) — ~95% of exposed never get disease.


Q27. Under India's revised NLEP classification, a patient with 3 skin lesions, no nerve involvement and negative slit-skin smear has

  • (a) multibacillary leprosy

  • (b) indeterminate leprosy requiring no treatment

  • (c) pure neural leprosy

  • (d) paucibacillary leprosy

Show answer

Answer: (d) — PB = 1–5, no nerve, smear negative.


Q28. The 2025 NLEP regimen for adult paucibacillary leprosy is

  • (a) dapsone alone for 12 months

  • (b) rifampicin and dapsone for 6 months

  • (c) rifampicin, clofazimine and dapsone for 6 months

  • (d) rifampicin, clofazimine and dapsone for 12 months

Show answer

Answer: (c) — MB: 12 months.


Q29. Erythema nodosum leprosum is

  • (a) a type 1 reversal reaction

  • (b) a type IV skin test

  • (c) a type 2 lepra reaction (immune complex)

  • (d) a drug allergy to dapsone

Show answer

Answer: (c) — Less common since clofazimine.


Q30. Contacts of a new leprosy patient in India receive

  • (a) dapsone for 6 months

  • (b) BCG revaccination only

  • (c) single-dose rifampicin as post-exposure prophylaxis

  • (d) nothing

Show answer

Answer: (c) — Leprosy notifiable since 2025.

Active Recall

From memory: describe the mycobacterial envelope and TB complex, how TB spreads and progresses (Ghon, Ranke, reactivation), the rapid tests and culture times, the NTEP DS-TB regimen and doses, the drug-resistance definitions and BPaLM, TB preventive treatment for contacts, the main NTM and their clues, and leprosy biology, classification, reactions and the 2025 NLEP regimen.